HEOR Publications

Publications for 2016

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H.

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b.

Hepatol Res. 2016 Mar;46(5):423-33. doi: 10.1111/hepr.12570. PubMed PMID:26440999.

Estimating the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in Korea

Kim DY, Han KH, Jun B, Kim TH, Park S, Ward T, Webster S, McEwan P. Estimating

the Cost-Effectiveness of One-Time Screening and Treatment for Hepatitis C in

Korea. PLoS One. 2017 Jan 6;12(1):e0167770. doi: 10.1371/journal.pone.0167770.

PubMed PMID: 28060834.

A clinician’s guide to the cost and health benefits of hepatitis C cure assessed from the individual patient perspective

McEwan P, Selvapatt N, Brown A, Thursz M, Bennett H, Webster S, Kalsekar A,

Yuan Y, Brenner M, Gordon J. A clinician’s guide to the cost and health benefits

of hepatitis C cure assessed from the individual patient perspective. Eur J

Gastroenterol Hepatol. 2017 Feb;29(2):208-214. doi: 10.1097/MEG.0000000000000773.

PubMed PMID: 27832039.

Value of Sustained Virologic Response in Patients with Hepatitis C as a Function of Time to Progression of End-Stage Liver Disease

Ward T, Gordon J, Jones B, Bennett H, Webster S, Kalsekar A, Yuan Y, Brenner

M, McEwan P. Value of Sustained Virologic Response in Patients with Hepatitis C

as a Function of Time to Progression of End-Stage Liver Disease. Clin Drug

Investig. 2017 Jan;37(1):61-70. doi: 10.1007/s40261-016-0458-z. PubMed PMID:

27587071.

Managing glycaemia in older people with type 2 diabetes: a retrospective, primary care based cohort study, with economic assessment of patient outcomes

Gordon J, McEwan P, Evans M, Puelles J, Sinclair A. Managing glycaemia in

older people with type 2 diabetes: a retrospective, primary care based cohort

study, with economic assessment of patient outcomes. Diabetes Obes Metab. 2016

Dec 27. doi: 10.1111/dom.12867. [Epub ahead of print] PubMed PMID: 28026911.

An alternative approach to modelling HbA1c trajectories in patients with type 2 diabetes mellitus

McEwan P, Bennett H, Qin L, Bergenheim K, Gordon J, Evans M. An alternative

approach to modelling HbA1c trajectories in patients with type 2 diabetes

mellitus. Diabetes Obes Metab. 2016 Dec 27. doi: 10.1111/dom.12865. [Epub ahead

of print] PubMed PMID: 28026908.

Tackling the burden of the hepatitis C virus in the UK: characterizing and assessing the clinical and economic consequences

Ward T, Gordon J, Bennett H, Webster S, Sugrue D, Jones B, Brenner M, McEwan

  1. Tackling the burden of the hepatitis C virus in the UK: characterizing and

assessing the clinical and economic consequences. Public Health. 2016

Dec;141:42-51. doi: 10.1016/j.puhe.2016.08.002. PubMed PMID: 27932014.

Hepatitis C disease transmission and treatment uptake: impact on the cost-effectiveness of new direct-acting antiviral therapies

Bennett H, Gordon J, Jones B, Ward T, Webster S, Kalsekar A, Yuan Y, Brenner

M, McEwan P. Hepatitis C disease transmission and treatment uptake: impact on the

cost-effectiveness of new direct-acting antiviral therapies. Eur J Health Econ.

2016 Nov 1. [Epub ahead of print] PubMed PMID: 27803989.

The Cost-Effectiveness of Alogliptin Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled Type 2 Diabetes Mellitus

 

Gordon J, McEwan P, Hurst M, Puelles J. The Cost-Effectiveness of Alogliptin

Versus Sulfonylurea as Add-on Therapy to Metformin in Patients with Uncontrolled

Type 2 Diabetes Mellitus. Diabetes Ther. 2016 Dec;7(4):825-845. PubMed PMID:

27787778; PubMed Central PMCID: PMC5118244.

The Health Economic Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type 1 Diabetes Mellitus

McEwan P, Bennett H, Fellows J, Priaulx J, Bergenheim K. The Health Economic

Value of Changes in Glycaemic Control, Weight and Rates of Hypoglycaemia in Type

1 Diabetes Mellitus. PLoS One. 2016 Sep 15;11(9):e0162441. doi:

10.1371/journal.pone.0162441. PubMed PMID: 27632534; PubMed Central PMCID:

PMC5025276.

Cost Effectiveness of IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting

 

Davies MJ, Glah D, Chubb B, Konidaris G, McEwan P. Cost Effectiveness of

IDegLira vs. Alternative Basal Insulin Intensification Therapies in Patients with

Type 2 Diabetes Mellitus Uncontrolled on Basal Insulin in a UK Setting.

Pharmacoeconomics. 2016 Sep;34(9):953-66. doi: 10.1007/s40273-016-0433-9. PubMed

PMID: 27438706.

The cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times daily (TID) as add-on therapy to titrated insulin glargine in patients with type 2 diabetes

Gordon J, McEwan P, Sabale U, Kartman B, Wolffenbuttel BH. The

cost-effectiveness of exenatide twice daily (BID) vs insulin lispro three times

daily (TID) as add-on therapy to titrated insulin glargine in patients with type

2 diabetes. J Med Econ. 2016 Dec;19(12):1167-1174. PubMed PMID: 27356188

The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UK

McEwan P, Bennett H, Ward T, Webster S, Gordon J, Kalsekar A, Yuan Y, Brenner

  1. The cost-effectiveness of daclatasvir-based regimens for the treatment of

hepatitis C virus genotypes 1 and 4 in the UK. Eur J Gastroenterol Hepatol. 2016

Feb;28(2):173-80. doi: 10.1097/MEG.0000000000000510. PubMed PMID: 26545086.

Methods applied in cost-effectiveness models for treatment strategies in type 2 diabetes mellitus and their use in Health Technology Assessments: a systematic review of the literature from 2008 to 2013.

Charokopou M, Sabater FJ, Townsend R, Roudaut M, McEwan P, Verheggen BG.

Methods applied in cost-effectiveness models for treatment strategies in type 2

diabetes mellitus and their use in Health Technology Assessments: a systematic

review of the literature from 2008 to 2013. Curr Med Res Opin. 2016;32(2):207-18.

doi: 10.1185/03007995.2015.1102722. Review. PubMed PMID: 26473650.

Publications for 2015

Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK

McEwan P, Bennett H, Ward T, Bergenheim K. Refitting of the UKPDS 68 Risk Equations to Contemporary Routine Clinical Practice Data in the UK Pharmacoeconomics 2015; 33(2):149-61

Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration

McEwan P, Gordon J, Evans M, Ward T, Bennett H, Bergenheim K. Estimating Cost-Effectiveness in Type 2 Diabetes: The Impact of Treatment Guidelines and Therapy Duration Med Decis Making 2015

Cost-effectiveness of dapagliflozin (Forxiga((R))) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries

Sabale U, Ekman M, Granstrom O, Bergenheim K, McEwan P. Cost-effectiveness of dapagliflozin (Forxiga((R))) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries Prim Care Diabetes 2015; 9(1):39-47

Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States

Foos V, Varol N, Curtis BH, Boye KS, Grant D, Palmer JL, McEwan P. Economic impact of severe and non-severe hypoglycemia in patients with Type 1 and Type 2 diabetes in the United States. J Med Econ. 2015; (1):1-39

Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C

McEwan P, Ward T, Bennett H, Kalsekar A, Webster S, Brenner M, Yuan Y. Estimating the clinical and economic benefit associated with incremental improvements in sustained virologic response in chronic hepatitis C. PLoS One 2015; 10(1):e0117334

Healthcare resource implications of hypoglcaemia-related hospital admissions and inpatient hypoglycaemia: retrospective record-linked cohort studies in England

McEwan P, Larsen Thorsed B, Wolden M, Jacobsen H, Evans M. Healthcare resource implications of hypoglcaemia-related hospital admissions and inpatient hypoglycaemia: retrospective record-linked cohort studies in England. BMJ Open Diabetes Res Care 2015; 3(1):e000057

The cost-effectiveness of dapaglifozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus

Charokopou M, McEwan P, Lister S, Callan L, Bergenheim K, Tolley K, Postema R, Townsend R, Roudaut M. The cost-effectiveness of dapaglifozin versus sulfonylurea as an add-on to metformin in the treatment of Type 2 diabetes mellitus. Diabet Med. 2015; doi: 10.1111/dme.12772

Characterising unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys

Gordon JP, McEwan PC, Maguire A, Sugrue DM, Puelles J.. Characterising unmet medical need and the potential role of new biologic treatment options in patients with ulcerative colitis and Crohn’s disease: a systematic review and clinician surveys. Eur J Gastroenterol Hepatol. 2015; 27(7):804-12

Assessing the long-term impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the relationship between treatment uptake and efficacy on future infections

Bennett H, McEwan P, Sugrue D, Jalsekar A, Yuan Y.. Assessing the long-tem impact of Treating Hepatitis C Virus (HCV)-Infected People Who Inject Drugs in the UK and the relationship between treatment uptake and efficacy on future infections. PLoS One. 2015; 10(5):e0125846

Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practice

Evans M, McEwan P.. Clinical and cost-effectiveness of insulin degludec: from clinical trials to clinical practive. J Comp Eff Res. 2015; 11:1-8 [Epub ahead of print]

Is antenatal screening for hepatitis C virus cost effective? A decade’s experience at a London centre

Selvapatt N, Ward T, Bailer H, Bennett H, Thorne C, See LM, Tudor-Williams G, Thurz M, McEwan P, Brown A. Is antenatal screening for hepatitis C virus cost effective? A decade’s experience at a London centre. J Hepatol. 2015; doi: 10.1016/j.jhep.2015.05.015 [Epub ahead of print]

Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model

McEwan P, Ward T, Bennett H, Bergenheim K. Validation of the UKPDS 82 risk equations within the Cardiff Diabetes Model. Cost Eff Resour Alloc. 2015 Aug 4;13:12.

Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study

Pockett RD, Watkins J, McEwan P, Meier G. Burden of Illness in UK Subjects with Reported Respiratory Infections Vaccinated or Unvaccinated against Influenza: A Retrospective Observational Study. PLoS One. 2015;10(8):e0134928.

Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Kamae I, Kobayashi M, Tang A, Kumada H. Estimating the cost-effectiveness of daclatasvir plus asunaprevir in difficult to treat Japanese patients chronically infected with hepatitis C genotype 1b. Hepatol Res. 2015 doi: 10.1111/hepr.12570. [Epub ahead of print]

Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy

Gordon JP, Evans M, Puelles J, McEwan PC. Factors Predictive of Weight Gain and Implications for Modeling in Type 2 Diabetes Patients Initiating Metformin and Sulfonylurea Combination Therapy. Diabetes Ther. 2015. [Epub ahead of print]

Publications for 2014

Review of utility values for economic modeling in type 2 diabetes

Beaudet A, Clegg J, Thuresson PO, Lloyd A, McEwan P. Review of utility values for economic modeling in type 2 diabetes Value Health 2014; 17(4):462-70

Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK

Bennett H, McEwan P, Bergenheim K, Gordon J. Assessment of Unmet Clinical Need in Type 2 Diabetic Patients on Conventional Therapy in the UK. Diabetes Ther 2014; 5(2):567-78

The economic burden of posttransplant events in renal transplant recipients in Europe

Chamberlain G, Baboolal K, Bennett H, Pockett RD, McEwan P, Sabater J, Sennfalt K. The economic burden of posttransplant events in renal transplant recipients in Europe Transplantation 2014; 97(8):854-61

Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation

Evans M, McEwan P, Foos V. Insulin degludec early clinical experience: does the promise from the clinical trials translate into clinical practice-a case-based evaluation J Med Econ 2014; p1-10

Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d’une enquête nationale rétrospective au Royaume-Uni Médecine des Maladies

Evans M, McEwan P, O’Shea R, George L. Efficacité en pratique clinique courante des incrétino-mimétiques dans le traitement du diabète de type 2 : résultats d’une enquête nationale rétrospective au Royaume-Uni Médecine des Maladies Métaboliques 2014; 8(2):177-83

Validation of the IMS CORE Diabetes Model

McEwan P, Foos V, Palmer JL, Lamotte M, Lloyd A, Grant D. Validation of the IMS CORE Diabetes Model Value Health 2014; 17(6):714-24

Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection

McEwan P, Ward T, Chen C-J, Lee M-H, Yang H-I, Kim R, L’Italien G, Yuan Y. Estimating the Incidence and Prevalence of Chronic Hepatitis C Infection in Taiwan Using Back Projection Value in Health Regional Issues 2014; 3(0):5-11

Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b

McEwan P, Ward T, Webster S, Yuan Y, Kalsekar A, Broglio K, Kamae I, Quintana M, Berry SM, Kobayashi M, Inoue S, Tang A, Kumada H. Estimating the Long-Term Clinical and Economic Outcomes of Daclatasvir Plus Asunaprevir in Difficult-to-Treat Japanese Patients Chronically Infected with Hepatitis C Genotype 1b Value in Health Regional Issues 2014; 3(0):136-45

Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands

van Haalen HG, Pompen M, Bergenheim K, McEwan P, Townsend R, Roudaut M. Cost effectiveness of adding dapagliflozin to insulin for the treatment of type 2 diabetes mellitus in the Netherlands Clin Drug Investig 2014; 34(2):135-46

Publications for 2013

A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice

Evans M, McEwan P, O’Shea R, George L. A retrospective, case-note survey of type 2 diabetes patients prescribed incretin-based therapies in clinical practice Diabetes Ther 2013; 4(1):27-40

Case note survey of T2D patients prescribed incretin therapies according to current recommendations in clinical practice

Evans M, McEwan P, O’Shea R, George L, Svendsen C, Clarke A. Case note survey of T2D patients prescribed incretin therapies according to current recommendations in clinical practice Prim Care Diabetes 2013; 7(1):83

Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom

Gordon J, Evans M, McEwan P, Bain S, Vora J. Evaluation of insulin use and value for money in type 2 diabetes in the United Kingdom Diabetes Ther 2013; 4(1):51-66

Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model

McEwan P, Kim R, Yuan Y. Assessing the cost utility of response-guided therapy in patients with chronic hepatitis C genotype 1 in the UK using the MONARCH model Appl Health Econ Health Policy 2013; 11(1):53-63

The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States

McEwan P, Ward T, Yuan Y, Kim R, L’Italien G. The impact of timing and prioritization on the cost-effectiveness of birth cohort testing and treatment for hepatitis C virus in the United States Hepatology 2013; 58(1):54-64

Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting

Palmer AJ, Clarke P, Gray A, Leal J, Lloyd A, Grant D, Palmer J, Foos V, Lamotte M, Hermann W, Barhak J, Willis M, Coleman R, Zhang P, McEwan P, Betz Brown J, Gerdtham U, Huang E, Briggs A, Carlsson KS, Valentine W. Computer modeling of diabetes and its complications: a report on the Fifth Mount Hood challenge meeting Value Health 2013; 16(4):670-85

Publications for 2012

Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis

Erhardt W, Bergenheim K, Duprat-Lomon I, McEwan P. Cost effectiveness of saxagliptin and metformin versus sulfonylurea and metformin in the treatment of type 2 diabetes mellitus in Germany: a Cardiff diabetes model analysis Clin Drug Investig 2012; 32(3):189-202

A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain

Gordon J, Lister S, Prettyjohns M, McEwan P, Tetlow A, Gabriel Z. A cost-utility study of the use of pregabalin in treatment-refractory neuropathic pain J Med Econ 2012; 15(2):207-18

Monitoring progress in the management of hip fractures in South Australia, Australia

Gordon J, Pham CT, Karnon J, Crotty M. Monitoring progress in the management of hip fractures in South Australia, Australia Arch Osteoporos 2012; 7(1-2):267-73

Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden

Granstrom O, Bergenheim K, McEwan P, Sennfalt K, Henriksson M. Cost-effectiveness of saxagliptin (Onglyza(R)) in type 2 diabetes in Sweden Prim Care Diabetes 2012; 6(2):127-36

The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland

Grzeszczak W, Czupryniak L, Kolasa K, Sciborski C, Lomon ID, McEwan P. The cost-effectiveness of saxagliptin versus NPH insulin when used in combination with other oral antidiabetes agents in the treatment of type 2 diabetes mellitus in Poland Diabetes Technol Ther 2012; 14(1):65-73

Coaching Older Adults and Carers to have their preferences Heard (COACH): A randomised controlled trial in an intermediate care setting (study protocol)

Masters S, Gordon J, Whitehead C, Davies O, Giles LC, Ratcliffe J. Coaching Older Adults and Carers to have their preferences Heard (COACH): A randomised controlled trial in an intermediate care setting (study protocol) Australas Med J 2012; 5(8):444-54

Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study

Neri L, McEwan P, Sennfalt K, Baboolal K. Characterizing the relationship between health utility and renal function after kidney transplantation in UK and US: a cross-sectional study Health Qual Life Outcomes 2012; 10:139

Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-2

Roberts M, Russell LB, Paltiel AD, Chambers M, McEwan P, Krahn M. Conceptualizing a model: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force–2 Value Health 2012; 15(6):804-11

System tools for system change

Willis CD, Mitton C, Gordon J, Best A. System tools for system change BMJ Qual Saf 2012; 21(3):250-62

Publications for 2011

Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C

Townsend R, McEwan P, Kim R, Yuan Y. Structural frameworks and key model parameters in cost-effectiveness analyses for current and future treatments of chronic hepatitis C Value Health 2011; 14(8):1068-77

Publications for 2010

Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database

Evans ML, Sharplin P, Owens DR, Chamberlain GH, Longman AJ, McEwan P. Insulin usage in type 2 diabetes mellitus patients in UK clinical practice: a retrospective cohort-based analysis using the THIN database British Journal of Diabetes & Vascular Disease 2010; 10(4):178-82

A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study

Gordon J, Pockett RD, Tetlow AP, McEwan P, Home PD. A comparison of intermediate and long-acting insulins in people with type 2 diabetes starting insulin: an observational database study Int J Clin Pract 2010; 64(12):1609-18

Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care

McEwan P, Bergenheim K, Yuan Y, Tetlow AP, Gordon JP. Assessing the relationship between computational speed and precision: a case study comparing an interpreted versus compiled programming language using a stochastic simulation model in diabetes care Pharmacoeconomics 2010; 28(8):665-74

A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes

McEwan P, Evans M, Bergenheim K. A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes Diabetes Obes Metab 2010; 12(7):623-30

Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model

McEwan P, Evans M, Kan H, Bergenheim K. Understanding the inter-relationship between improved glycaemic control, hypoglycaemia and weight change within a long-term economic model Diabetes Obes Metab 2010; 12(5):431-6

A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK

Morgan CL, Griffin A, Chamberlain GH, Turkiendorf A, McEwan P, Evans LM, Owens DR. A longitudinal study into the new and long-term use of self-monitoring blood glucose strips in the UK Diabetes Ther 2010; 1(1):1-9

The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain

Pockett RD, Castellano D, McEwan P, Oglesby A, Barber BL, Chung K. The hospital burden of disease associated with bone metastases and skeletal-related events in patients with breast cancer, lung cancer, or prostate cancer in Spain Eur J Cancer Care (Engl) 2010; 19(6):755-60

Recent epidemiological results of thyroid cancer in the most radiated territory in Poland

Tukiendorf A, Miszczyk L, McEwan P. Recent epidemiological results of thyroid cancer in the most radiated territory in Poland Cent Eur J Public Health 2010; 18(3):157-60

Publications for 2009

Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control

Morgan CL, McEwan P, Tukiendorf A, Robinson PA, Clemens A, Plumb JM. Warfarin treatment in patients with atrial fibrillation: observing outcomes associated with varying levels of INR control Thromb Res 2009; 124(1):37-41

Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis

Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Switching from premixed insulin to glargine-based insulin regimen improves glycaemic control in patients with type 1 or type 2 diabetes: a retrospective primary-care-based analysis Cardiovasc Diabetol 2009; 8:9

Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study

Sharplin P, Gordon J, Peters JR, Tetlow AP, Longman AJ, McEwan P. Improved glycaemic control by switching from insulin NPH to insulin glargine: a retrospective observational study Cardiovasc Diabetol 2009; 8:3

Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha

Wechowski J, Connolly M, Schneider D, McEwan P, Kennedy R. Cost-saving treatment strategies in in vitro fertilization: a combined economic evaluation of two large randomized clinical trials comparing highly purified human menopausal gonadotropin and recombinant follicle-stimulating hormone alpha Fertil Steril 2009; 91(4):1067-76

Publications for 2008

The cost of renal dialysis in a UK setting–a multicentre study

Baboolal K, McEwan P, Sondhi S, Spiewanowski P, Wechowski J, Wilson K. The cost of renal dialysis in a UK setting–a multicentre study Nephrol Dial Transplant 2008; 23(6):1982-9

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom

Woehl A, Evans M, Tetlow AP, McEwan P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom Cardiovasc Diabetol 2008; 7:24

Publications for 2007

Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model

Caro J, Stillman I, Danel A, Getsios D, McEwan P. Cost effectiveness of rimonabant use in patients at increased cardiometabolic risk: estimates from a Markov model Journal of Medical Economics 2007; 10(3):239-54

Use of evidence in economic decision models: practical issues and methodological challenges

Cooper NJ, Sutton AJ, Ades AE, Paisley S, Jones DR. Use of evidence in economic decision models: practical issues and methodological challenges Health Econ 2007; 16(12):1277-86

The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

Currie CJ, Poole CD, Tetlow T, Holmes P, McEwan P. The outcome of care in people with type 1 and type 2 diabetes following switching to treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis Current Medical Research and Opinion 2007; 23(s1):S33-S9

Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy

Girling AJ, Freeman G, Gordon JP, Poole-Wilson P, Scott DA, Lilford RJ. Modeling payback from research into the efficacy of left-ventricular assist devices as destination therapy Int J Technol Assess Health Care 2007; 23(2):269-77

Cost-utility analysis when not everyone wants the treatment: modeling split-choice bias

Lilford R, Girling A, Braunholtz D, Gillett W, Gordon J, Brown CA, Stevens A. Cost-utility analysis when not everyone wants the treatment: modeling split-choice bias Med Decis Making 2007; 27(1):21-6

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK

McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 1 diabetes in the UK Current Medical Research and Opinion 2007; 23(s1):S7-S19

Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK

McEwan P, Poole CD, Tetlow T, Holmes P, Currie CJ. Evaluation of the cost-effectiveness of insulin glargine versus NPH insulin for the treatment of type 2 diabetes in the UK Current Medical Research and Opinion 2007; 23(s1):S21-S31

The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis

Poole CD, Tetlow T, McEwan P, Holmes P, Currie CJ. The prescription cost of managing people with type 1 and type 2 diabetes following initiation of treatment with either insulin glargine or insulin detemir in routine general practice in the UK: a retrospective database analysis Current Medical Research and Opinion 2007; 23(s1):S41-S8

Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting

The Mount Hood 4 Modeling Group. Computer modeling of diabetes and its complications: a report on the Fourth Mount Hood Challenge Meeting Diabetes Care 2007; 30(6):1638-46

An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial

Wechowski J, Connolly M, McEwan P, Kennedy R. An economic evaluation of highly purified HMG and recombinant FSH based on a large randomized trial Reprod Biomed Online 2007; 15(5):500-6

An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis

Wechowski J, Connolly M, Woehl A, Tetlow A, McEwan P, Burroughs A, Currie CJ, Bhatt A. An economic evaluation of vasoactive agents used in the United Kingdom for acute bleeding oesophageal varices in patients with liver cirrhosis Curr Med Res Opin 2007; 23(7):1481-91

Publications for 2006

Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin

Currie CJ, Jones M, Goodfellow J, McEwan P, Morgan CL, Emmas C, Peters JR. Evaluation of survival and ischaemic and thromboembolic event rates in patients with non-valvar atrial fibrillation in the general population when treated and untreated with warfarin Heart 2006; 92(2):196-200

The impact of the overactive bladder on health-related utility and quality of life

Currie CJ, McEwan P, Poole CD, Odeyemi IA, Datta SN, Morgan CL. The impact of the overactive bladder on health-related utility and quality of life BJU Int 2006; 97(6):1267-72

Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes

Currie CJ, Morgan CL, Poole CD, Sharplin P, Lammert M, McEwan P. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes Curr Med Res Opin 2006; 22(8):1523-34

Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK

McEwan P, Dixon S, Baboolal K, Conway P, Currie CJ. Evaluation of the cost effectiveness of sirolimus versus tacrolimus for immunosuppression following renal transplantation in the UK Pharmacoeconomics 2006; 24(1):67-79

Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster)

McEwan P, Peters JR, Bergenheim K, Currie CJ. Evaluation of the costs and outcomes from changes in risk factors in type 2 diabetes using the Cardiff stochastic simulation cost-utility model (DiabForecaster) Curr Med Res Opin 2006; 22(1):121-9

Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications

Morgan CL, McEwan P, Morrissey M, Peters JR, Poole C, Currie CJ. Characterization and comparison of health-related utility in people with diabetes with various single and multiple vascular complications Diabet Med 2006; 23(10):1100-5

Publications for 2005

Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel

Bagust A, McEwan P. Guidelines for computer modeling of diabetes and its complications: response to American Diabetes Association Consensus Panel Diabetes Care 2005; 28(2):500

Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas

Biswas M, Smith J, Jadon D, McEwan P, Rees DA, Evans LM, Scanlon MF, Davies JS. Long-term remission following withdrawal of dopamine agonist therapy in subjects with microprolactinomas Clin Endocrinol (Oxf) 2005; 63(1):26-31

Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus

Cockcroft JR, Wilkinson IB, Evans M, McEwan P, Peters JR, Davies S, Scanlon MF, Currie CJ. Pulse pressure predicts cardiovascular risk in patients with type 2 diabetes mellitus Am J Hypertens 2005; 18(11):1463-7

Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population

Currie CJ, McEwan P, Emmas C, Morgan CL, Peters JR. Anticoagulation in patients with non-valvular atrial fibrillation: an evaluation of stability and early factors that predict longer-term stability on warfarin in a large UK population Curr Med Res Opin 2005; 21(12):1905-13

The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects

Currie CJ, McEwan P, Peters JR, Patel TC, Dixon S. The routine collation of health outcomes data from hospital treated subjects in the Health Outcomes Data Repository (HODaR): descriptive analysis from the first 20,000 subjects Value Health 2005; 8(5):581-90

The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications

Currie CJ, Morgan CL, Dixon S, McEwan P, Marchant N, Bearne A, Sharplin P, Peters JR. The financial costs of hospital care for people with diabetes who have single and multiple macrovascular complications Diabetes Res Clin Pract 2005; 67(2):144-51

Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population

Jones M, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population Heart 2005; 91(4):472-7

Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom

McEwan P, Baboolal K, Conway P, Currie CJ. Evaluation of the cost-effectiveness of sirolimus versus cyclosporin for immunosuppression after renal transplantation in the United Kingdom Clin Ther 2005; 27(11):1834-46

Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years

McEwan P, Baboolal K, Dixon S, Conway P, Currie CJ. Patterns of graft and patient survival following renal transplantation and evaluation of serum creatinine as a predictor of survival: a review of data collected from one clinical centre over 34 years Curr Med Res Opin 2005; 21(11):1793-800

Insulin pumps: more consultation was needed

Palmer AJ, Tucker DM, Ray JA, Valentine WJ, Currie C, McEwan P, Brandle M. Insulin pumps: more consultation was needed Bmj 2005; 331(7521):905-6

The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss

Rowe R, Cowx M, Poole C, McEwan P, Morgan C, Walker M. The effects of orlistat in patients with diabetes: improvement in glycaemic control and weight loss Curr Med Res Opin 2005; 21(11):1885-90

Publications for 2004

Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death

Currie CJ, Morgan CL, Dixon S, McEwan P, Marchant N, Bearne A, Sharplin P, Peters JR. Comparative estimates of the financial burden to the UK health system of hospital care for people with and without diabetes in the year before death Diabetes Res Clin Pract 2004; 65(3):267-74

Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service

Currie CJ, Patel TC, McEwan P, Dixon S. Evaluation of the future supply and demand for blood products in the United Kingdom National Health Service Transfus Med 2004; 14(1):19-24

Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository

Dixon S, Currie CJ, McEwan P. Utility values for obesity and preliminary analysis of the Health Outcomes Data Repository Expert Rev Pharmacoecon Outcomes Res 2004; 4(6):657-65

Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate

Evans M, McEwan P, Peters JR, Currie CJ. Should we routinely measure a proxy for insulin resistance as well as improve our modelling techniques to better predict the likelihood of coronary heart disease in people with type 2 diabetes? For debate Diabetes Obes Metab 2004; 6(4):299-307

Evaluating the performance of the Framingham risk equations in a population with diabetes

McEwan P, Williams JE, Griffiths JD, Bagust A, Peters JR, Hopkinson P, Currie CJ. Evaluating the performance of the Framingham risk equations in a population with diabetes Diabet Med 2004; 21(4):318-23

Publications for 2003

Estimating the health utility of treatment in adults with growth hormone deficiency

Dixon S, McEwan P, Currie C. Estimating the health utility of treatment in adults with growth hormone deficiency Journal of Outcomes Research 2003; 7:1-12

Study 1: a fresh look at early serum creatinine at one, two, and three years as a surrogate marker for long-term outcomes in renal immunosuppression

McEwan PC, Currie CJ, Conway P, Moore R, Jurewicz A, Baboolal K. Study 1: a fresh look at early serum creatinine at one, two, and three years as a surrogate marker for long-term outcomes in renal immunosuppression Transplantation Reviews 2003; 17(4):S41

Publications for 2000

Forms of macro-vascular disease in diabetes are associated with different patterns of modifiable risk factors

McEwan PC, Peters J, Currie CJ, Hopkinson P, Griffiths JD, Williams JE. Forms of macro-vascular disease in diabetes are associated with different patterns of modifiable risk factors Diabetes Res Clin Pract 2000; 50:345

Assessing the framingham risk equations for predicting coronary heart disease in type 2 diabetes

McEwan PC, Peters J, Currie CJ, Patrick H, Griffiths JD, Williams JE. Assessing the framingham risk equations for predicting coronary heart disease in type 2 diabetes Diabetes Res Clin Pract 2000; 50:195